No Data
TIGERMED (300347.SZ): Has repurchased a total of 1.1337% of shares.
On March 4, Gelonghui reported that TIGERMED (300347.SZ) announced that as of February 28, 2025, the company's dedicated securities repurchase account accumulated the repurchase of 9,806,300 shares through centralized bidding, accounting for 1.1337% of the company's total share capital and 1.3219% of the company's A-share total share capital, with a highest Fill Price of 62.00 yuan/share and a lowest Fill Price of 48.17 yuan/share, for a total transaction amount of approximately 0.5 billion yuan (excluding transaction fees).
Trending Industry Today: PHARMARON Leads Losses In CRO Stocks
Hong Kong stocks move | CRO Concept stocks plunged sharply in the morning as the USA plans to tighten investment restriction policies. Institutions say there is a risk of short-term impact on market sentiment.
CRO Concept stocks plummeted in the morning; as of the time of writing, WUXI APPTEC (02359) is down 9%, trading at 63.7 Hong Kong dollars; FRONTAGE (01521) is down 6.99%, trading at 1.33 Hong Kong dollars; PHARMARON (03759) is down 5.83%, trading at 18.1 Hong Kong dollars; TIGERMED (03347) is down 5.7%, trading at 36.4 Hong Kong dollars.
Trending Industry Today: WUXI BIO Leads Losses In CRO Stocks
The CRO Sector is under pressure, WUXI BIO (02269) fell 6.73% as it is rumored that the USA intends to restrict investments by Chinese enterprises in several strategic areas.
Kingwu Financial News | The CRO Sector is under pressure, WUXI BIO (02269) fell by 6.73%, WUXI APPTEC (02359) fell by 5.57%, VIVA BIOTECH (01873) fell by 3.77%, TIGERMED (03347) fell by 3.5%, PHARMARON (03759) fell by 3.12%. According to media reports citing anonymous USA officials, President Trump signed an order directing the Treasury Department's Committee on Foreign Investment in the USA (CFIUS) to continue restricting Chinese companies from making investments in several strategic sectors in the USA. Reports indicate that the purpose of the memorandum is to ensure USA National Security while requiring
TIGERMED (03347.HK) repurchased 0.1674 million A-shares at a cost of 10.0502 million yuan on February 21.
Gelonghui, on February 21, announced that TIGERMED (03347.HK) spent 10.0502 million yuan to repurchase 0.1674 million A-shares on February 21, 2025, at a repurchase price of 59.4-62 yuan per share.
